Effect of monoterpenes on ex vivo transungual delivery of itraconazole for the management of onychomycosis
- PMID: 32043759
- DOI: 10.1111/jocd.13317
Effect of monoterpenes on ex vivo transungual delivery of itraconazole for the management of onychomycosis
Abstract
Background: Onychomycosis, a fungal nail infection, is an important problem as it may cause local pain, paresthesia, difficulties in performing activities of daily life, and impair social interactions. Systemic treatment of onychomycosis presents safety issues due to possible drug-drug interactions and severe side effects. Although topical therapy of onychomycosis is advantageous due to its localized effect, the efficacy of such therapy depends on achieving effective concentrations of antifungal agents at the infection site. An approach to reach to this end would be driving benefit from synergic activity of antifungal agents for example itraconazole and monoterpenes. However, because of low transungual penetration of itraconazole, a molecule with high molecular weight and very low water-solubility, the effect of the latter compounds on itraconazole nail delivery should be investigated, which was the aim of this study.
Methods: Ex vivo permeation experiments were carried out through soaking the nail clippings of ten healthy volunteers in control and working solutions containing itraconazole (1 mg mL-1 ) and itraconazole (1 mg mL-1 ) plus 6% of each monoterpene including camphor, eucalyptol, menthol, and thymol, respectively, for 36 hours. The amount of itraconazole in nail clippings was quantified hereafter using a validated HPLC method.
Results: Statistical analysis showed that itraconazole transungual permeation was not influenced by the studied monoterpenes (P value > .05).
Conclusion: These results provided a new perspective for designing topical dosage forms for the treatment of onychomycosis.
Keywords: itraconazole; monoterpenes; nail; transungual.
© 2020 Wiley Periodicals, Inc.
References
REFERENCES
-
- Barot BS, Parejiya PB, Patel HK, Mehta DM, Shelat PK. Drug delivery to the nail: therapeutic options and challenges for onychomycosis. Crit Rev Ther Drug Carrier Syst. 2014;31(6):459-494.
-
- Lipner SR, Scher RK. Part II: onychomycosis: treatment and prevention of recurrence. J Am Acad Dermatol. 2018;80:S0190.
-
- Lipner SR. Pharmacotherapy for onychomycosis: new and emerging treatments. Expert Opin Pharmacother. 2019;20:1-11.
-
- Murdan S. Drug delivery to the nail following topical application. Int J Pharm. 2002;236(1-2):1-26.
-
- Shivakumar HN, Repka MA, Narasimha MS. Transungual drug delivery: an update. J Drug Del Sci Tech. 2014;24(3):301-310.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
